| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $4,226,448 | 13 | 100 |
| LEVIN ARTHUR A | director | 0 | $0 | 1 | $127,367 | $-127,367 |
| Moriarty John B | Chief Legal Officer | 0 | $0 | 1 | $171,474 | $-171,474 |
| Calderaro Charles III | Chief Technical Officer | 0 | $0 | 1 | $269,201 | $-269,201 |
| McCarthy Teresa | Chief Human Resources Officer | 0 | $0 | 2 | $354,138 | $-354,138 |
| MacLean Michael F | Chief Financial Officer | 0 | $0 | 2 | $471,650 | $-471,650 |
| Hughes Steven George | Chief Medical Officer | 0 | $0 | 2 | $526,045 | $-526,045 |
| Flanagan W. Michael | Chief Scientific Officer | 0 | $0 | 2 | $644,790 | $-644,790 |
| Boyce Sarah | President and CEO | 0 | $0 | 2 | $1.66M | $-1.66M |
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various …
Over the last 12 months, insiders at Atrium Therapeutics, Inc. have bought $0 and sold $4.23M worth of Atrium Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Atrium Therapeutics, Inc. have bought $0 and sold $19.59M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 800,000 shares for transaction amount of $14.4M was made by RTW INVESTMENTS, LP (10 percent owner) on 2021‑08‑04.
| 2026-01-21 | Sale | Boyce Sarah | President and CEO | 14,387 0.0095% | $72.45 | $1.04M | ||
| 2026-01-21 | Sale | McCarthy Teresa | Chief Human Resources Officer | 2,929 0.0019% | $72.45 | $212,206 | ||
| 2026-01-21 | Sale | Flanagan W. Michael | Chief Scientific Officer | 6,534 0.0043% | $72.45 | $473,388 | ||
| 2026-01-21 | Sale | MacLean Michael F | Chief Financial Officer | 4,542 0.003% | $72.45 | $329,068 | ||
| 2026-01-21 | Sale | Hughes Steven George | Chief Medical Officer | 4,895 0.0032% | $72.45 | $354,643 | ||
| 2026-01-21 | Sale | LEVIN ARTHUR A | director | 1,758 0.0012% | $72.45 | $127,367 | ||
| 2026-01-07 | Sale | Boyce Sarah | President and CEO | 8,576 0.0065% | $72.23 | $619,444 | ||
| 2026-01-07 | Sale | McCarthy Teresa | Chief Human Resources Officer | 1,965 0.0015% | $72.23 | $141,932 | ||
| 2026-01-07 | Sale | Flanagan W. Michael | Chief Scientific Officer | 2,373 0.0018% | $72.23 | $171,402 | ||
| 2026-01-07 | Sale | Moriarty John B | Chief Legal Officer | 2,374 0.0018% | $72.23 | $171,474 | ||
| 2026-01-07 | Sale | MacLean Michael F | Chief Financial Officer | 1,974 0.0015% | $72.23 | $142,582 | ||
| 2026-01-07 | Sale | Calderaro Charles III | Chief Technical Officer | 3,727 0.0028% | $72.23 | $269,201 | ||
| 2026-01-07 | Sale | Hughes Steven George | Chief Medical Officer | 2,373 0.0018% | $72.23 | $171,402 | ||
| 2025-10-15 | Sale | McCarthy Teresa | Chief Human Resources Officer | 20,000 0.0154% | $50.15 | $1M | ||
| 2025-10-03 | Sale | Mosbrooker Eric | Chief Commercial Officer | 6,562 0.0053% | $45.38 | $297,771 | ||
| 2025-09-22 | Sale | Hughes Steven George | Chief Medical Officer | 2,208 0.0016% | $40.58 | $89,601 | ||
| 2025-09-15 | Sale | McCarthy Teresa | Chief Human Resources Officer | 15,000 0.012% | $41.41 | $621,143 | ||
| 2025-09-15 | Sale | Hughes Steven George | Chief Medical Officer | 1,542 0.0014% | $45.41 | $70,022 | ||
| 2025-09-11 | Sale | Flanagan W. Michael | Chief Scientific Officer | 20,000 0.0147% | $38.94 | $778,702 | ||
| 2025-09-05 | Sale | Boyce Sarah | President and CEO | 50,000 0.0385% | $49.95 | $2.5M |
| Increased Positions | 221 | +61.05% | 7M | +41.18% |
| Decreased Positions | 166 | -45.86% | 9M | -54.17% |
| New Positions | 149 | New | 5M | New |
| Sold Out Positions | 79 | Sold Out | 3M | Sold Out |
| Total Postitions | 417 | +15.19% | 14M | -12.99% |
| Fmr Llc | $1.56M | 14.3% | 21.59M | +5M | +33.36% | 2025-09-30 |
| Janus Henderson Group Plc | $1.05M | 9.62% | 14.52M | +4M | +34.75% | 2025-09-30 |
| Vanguard Group Inc | $953,145.00 | 8.76% | 13.22M | +4M | +42.94% | 2025-09-30 |
| Rtw Investments, Lp | $819,981.00 | 7.53% | 11.37M | +2M | +18.23% | 2025-09-30 |
| Wellington Management Group Llp | $725,700.00 | 6.67% | 10.07M | +815,497 | +8.82% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $705,673.00 | 6.48% | 9.79M | -1M | -9.45% | 2025-09-30 |
| Blackrock, Inc. | $663,506.00 | 6.09% | 9.2M | -134,255 | -1.44% | 2025-09-30 |
| Ra Capital Management, L.P. | $623,018.00 | 5.72% | 8.64M | +1M | +18.92% | 2025-09-30 |
| Avoro Capital Advisors Llc | $551,205.00 | 5.06% | 7.64M | +595,000 | +8.44% | 2025-09-30 |
| State Street Corp | $352,470.00 | 3.24% | 4.89M | +687,123 | +16.35% | 2025-09-30 |